Ananda Pharma's Strategic Bet on Cannabidiol for Cancer Patients

LONDON, UK – July 06, 2026 – UK-based biopharmaceutical firm Ananda Pharma has initiated a critical new phase in the development of its novel drug, MRX1, potentially offering hope to millions of cancer patients suffering from a debilitating side effect of their treatment. The company announced the delivery of its investigational cannabidiol-based medicine to the University of Edinburgh, paving the way for the ACTiON Phase 2 clinical trial for Chemotherapy-Induced Peripheral Neuropathy (CIPN).

This milestone marks a significant strategic step for Ananda, moving its lead candidate from a successful first-in-human study into a pivotal efficacy trial. With participant screening now underway, the company is on the cusp of dosing its first patient in a study that addresses a severe unmet medical need and highlights a sophisticated strategy for navigating the complex landscape of cannabinoid therapeutics.

The Unmet Need: Tackling a Debilitating Consequence of Cancer Care

Chemotherapy, while a cornerstone of modern oncology, often comes with a heavy price. One of the most frequent and distressing side effects is CIPN, a condition characterized by nerve damage that causes chronic pain, tingling, numbness, and burning sensations, typically in the hands and feet. For patients, the impact is profound, severely impairing quality of life long after cancer treatment has concluded.

The scale of the problem is immense. In the UK alone, over 140,000 new cases are diagnosed each year, with a prevalence of nearly one million patients. In the United States, the figure rises to 400,000 new patients annually, contributing to an estimated $2.5 billion in healthcare costs. Beyond the persistent pain, CIPN carries a more insidious risk: its severity often forces oncologists to reduce chemotherapy dosages or halt treatment altogether, a decision that can directly compromise a patient's chance of survival. Despite its prevalence and severity, there are no reliably effective therapies for preventing or treating CIPN, making it a critical focus for medical innovation.

A Strategic Approach to Cannabidiol Drug Development

Ananda Pharma is positioning itself to fill this therapeutic void through a highly strategic approach to drug development. The company's lead asset, MRX1, is a patent-pending oral solution of cannabidiol (CBD). Critically, the formulation is effectively free of THC, the psychoactive component of cannabis. This is a deliberate strategic choice, allowing for high-dose administration without the risk of intoxication and significantly de-risking the regulatory pathway by separating the therapeutic from the recreational.

The company's strategy is built on a foundation of rigorous scientific validation. Earlier this year, Ananda successfully completed a Phase 1 pharmacokinetic trial in Australia, which demonstrated a clean safety profile for MRX1. The study, involving 20 participants, reported no moderate or severe adverse events and, crucially, no clinically significant changes in liver function—a key safety concern for some high-dose CBD products. This robust safety and pharmacokinetic data is not just a prerequisite for the current Phase 2 trials; it is a strategic asset that underpins the company's plan to pursue an accelerated 505(b)(2) regulatory pathway with the US FDA, which allows for leveraging existing safety data to streamline approval.

Further demonstrating its strategic focus, Ananda is not a single-asset company. MRX1 is also being evaluated in the ENDOCAN trial, another Phase 2 study for endometriosis-associated pain. This dual-pronged approach targets two large, distinct markets characterized by chronic pain and a lack of effective treatments, diversifying risk and maximizing the potential value of its core technology.

The Power of Partnership: A UK Research Collaboration

The ACTiON trial is not just a corporate milestone; it is a testament to the power of the UK's life sciences ecosystem. The trial is a collaborative effort between Ananda Pharma, the prestigious University of Edinburgh, and the National Institute for Health and Care Research (NIHR), which is funding the study through an Efficacy and Mechanism Evaluation (EME) grant.

This "golden triangle" of industry innovation, academic excellence, and public funding is a model for accelerating medical breakthroughs. The NIHR's EME grant is particularly significant. This program supports robust clinical trials for interventions that have already demonstrated safety and show a convincing signal of potential benefit. The funding validates the scientific premise of using MRX1 for CIPN and enables a comprehensive study design that will not only assess efficacy but also explore the drug's mechanism of action through advanced brain imaging and biomarker analysis.

Leading the trial is Professor Marie Fallon, the St Columba's Hospice Chair of Palliative Medicine at the University of Edinburgh. Ananda's CEO, Melissa Sturgess, commented, "We are delighted to be working on this clinical trial alongside Professor Marie Fallon... Professor Fallon is a global key opinion leader in CIPN and thus brings significant gravitas to the trial design and importance." Her involvement ensures the trial is conducted with the highest scientific and ethical rigor, lending immense credibility to the program.

Navigating the Path to Market

The ACTiON trial itself is designed for scientific rigor. As a double-blind, placebo-controlled, crossover study targeting 92 participants, its results will provide a clear signal of MRX1's efficacy. The trial will assess not only the drug's ability to reduce pain but also its impact on quality of life and healthcare utilization—key metrics for securing reimbursement and driving adoption if the drug proves successful.

By pursuing a formal, regulatory-approved pharmaceutical path, Ananda Pharma is strategically differentiating itself from the broader, less-regulated consumer CBD market. A successful outcome for MRX1 would position it as a potential first-in-class, evidence-based therapy prescribed by doctors and integrated into standard cancer care protocols. With a clear unmet need and a multi-billion dollar market at stake, the progress of the ACTiON trial will be closely watched by patients, clinicians, and investors alike. The company has confirmed it will provide further updates once the first participant receives their first dose, marking the next key inflection point in its journey.